<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365933</url>
  </required_header>
  <id_info>
    <org_study_id>EYP001-203</org_study_id>
    <nct_id>NCT04365933</nct_id>
  </id_info>
  <brief_title>A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir</brief_title>
  <official_title>A Phase 2a Open-label Study of the Oral Farnesoid X Receptor (FXR) Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B (CHB) Patients in Combination With Pegylated Interferon alpha2a (Peg-IFN) Alone and With Entecavir (ETV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enyo Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enyo Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi centre, two parallel arm, randomized, open-label, Phase 2a experimental study&#xD;
      of oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral&#xD;
      effect when administered to non-treated (treatment naive or off treatment) chronic Hepatitis&#xD;
      B (CHB) patients in combination with entecavir (ETV) and pegylated interferon alpha2a&#xD;
      (peg-IFN). An experimental treatment period of 16 weeks will be followed by a 24 week&#xD;
      maintenance period with ETV standard of care (SoC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In total 30 eligible patients will be enrolled and randomized at approximately 7 study sites.&#xD;
&#xD;
      Patients will be randomized prior to study drug (EYP001a, ETV and peg-IFN) administration on&#xD;
      Day 1 in the ratio of 1:1 into 2 treatment arms:&#xD;
&#xD;
        -  Arm 1: EYP001a QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg&#xD;
           or 90 µg) QW (± 3 days) (15 patients)&#xD;
&#xD;
        -  Arm 2: EYP001a QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW (±&#xD;
           3 days) (15 patients)&#xD;
&#xD;
      Patients enrolled in the study will be assessed as outpatients. Patient screening will occur&#xD;
      no more than 37 days prior to the Day 1 visit. Eligible patients will undergo further&#xD;
      assessments on Day 1 to qualify for study drug administration on Day 1.&#xD;
&#xD;
      The visits during the study are planned as below:&#xD;
&#xD;
        -  Screening visit: 5 weeks (37 days)&#xD;
&#xD;
        -  16 weeks treatment period&#xD;
&#xD;
        -  24 weeks maintenance period. During maintenance period patients are kept on ETV until&#xD;
           the end of the trial at Week 40.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment-emergent adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of Treatment-emergent adverse events including serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of HBsAg decline</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measurement of HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of HBsAg decline</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measurement of HBsAg decline (Δ log10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HBV-DNA decline</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measurement of HBV-DNA decline (Δ log10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HBV-pgRNA decline</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measurement of HBV-pgRNA decline (Δ log10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HBcrAg decline</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measurement of HBcrAg decline (Δ log10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of EYP001a - Pharmacokinetic</measure>
    <time_frame>20 weeks</time_frame>
    <description>Assessment of fasted plasma concentrations of EYP001a or any active metabolites using a validated liquid chromatography-mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of C4 - Pharmacodynamic biomarker</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assessment of concentrations of plasma C4 (7α hydroxy 4 cholesten 3 one)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of FGF19 - Pharmacodynamic biomarker</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assessment of concentrations of plasma FGF19 over time (Fibroblast Growth Factor 19)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Bile Acids - Pharmacodynamic biomarker</measure>
    <time_frame>40 weeks</time_frame>
    <description>Assessment of concentrations over time of plasma Bile Acids (chenodeoxycholic acid, deoxycholic acid, lithocholic acid)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EYP001a Dose A QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EYP001a</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alpha2a</intervention_name>
    <description>Subcutaneous</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has given voluntary written informed consent before performance of any study related&#xD;
             procedure.&#xD;
&#xD;
          -  Are treatment naive or without HBV treatment for at least 60 days or 5 times the&#xD;
             elimination half-life, whichever is longer.&#xD;
&#xD;
          -  Patient has CHB:&#xD;
&#xD;
               1. HBV DNA ≥ 20,000 IU/mL for HBeAg positive and ≥2'000 for HBeAg negative and&#xD;
&#xD;
               2. HBsAg ≥ 2.5 log10 IU/mL.&#xD;
&#xD;
          -  Has liver imaging to screen for hepatocellular carcinoma or concomitant&#xD;
             pancreaticobiliary disease either in the prior 6 months or at screening.&#xD;
&#xD;
          -  Patient is not of childbearing potential or, if of childbearing potential, is not&#xD;
             pregnant as confirmed by a negative serum human chorionic gonadotropin test at&#xD;
             screening and is not planning a pregnancy during the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is an employee of a clinical research organization, vendor, or Sponsor involved with&#xD;
             this study.&#xD;
&#xD;
          -  Has known hepatocellular carcinoma or pancreaticobiliary disease.&#xD;
&#xD;
          -  Neutropenia (defined by two confirmed values during Screening period of &lt; 1500/μL).&#xD;
&#xD;
          -  Has Gilbert syndrome.&#xD;
&#xD;
          -  Shows evidence of worsening liver tests, defined as either a confirmed (2 assessments&#xD;
             at least 3 days apart) increase &gt; 2 ULN ALT or AST or an increase of &gt; 1.5 × baseline&#xD;
             value of TBL or associated with clinical signs or symptoms of liver impairment.&#xD;
&#xD;
          -  Has known or suspected non-CHB liver disease&#xD;
&#xD;
          -  History of cirrhosis or liver decompensation, including ascites, hepatic&#xD;
             encephalopathy, or presence of oesophageal varices.&#xD;
&#xD;
          -  Probable or possible F4 stage with a vibration controlled transient elastography&#xD;
             (VCTE) &gt; 11.7 kPa leads to exclusion&#xD;
&#xD;
          -  Has known history of alcohol abuse or daily heavy alcohol consumption&#xD;
&#xD;
          -  Has any of the following exclusionary laboratory results at screening:&#xD;
&#xD;
               1. ALT &gt; 2 × ULN, AST &gt; 2 × ULN&#xD;
&#xD;
               2. INR &gt; 1.2 × ULN, (normal range is 0.8 to 1.2)&#xD;
&#xD;
               3. Platelet count &lt; 100 G/L&#xD;
&#xD;
               4. Estimated glomerular filtration rate &lt; 50 mL/min/1.73m2 (the Modification of Diet&#xD;
                  in Renal Disease formula)&#xD;
&#xD;
               5. Thyroid-stimulating hormone &gt; 1.5 × ULN or abnormal free triiodothyronine or free&#xD;
                  thyroxine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site HK01</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR01</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site TW03</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site TW04</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site TW01</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site TW02</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

